XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTSOn October 31, 2022, we announced that our collaboration partner, KKC, submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. This submission triggers KKC's obligation to make an aggregate of $35.0 million to us in milestone payments and payments under the 2022 Amendment. In accordance with the terms of the 2022 Amendment, we expect to receive these payments during the fourth quarter of 2022.